How did AstraZeneca's revenue and expenses perform in Q4 2024?

**AstraZeneca's revenue for Q4 2024 exceeded expectations, but the specific revenue by business and expenses ratio were not provided.** Here's a detailed analysis based on the available data:

1. **Revenue Performance**:
- AstraZeneca reported total revenues of $13.57 billion for the quarter, surpassing the consensus estimate of $13.08 billion.
- The company's revenue grew by 18.0% year-over-year, indicating a strong performance across its business segments.
2. **Business Segment Insights**:
- Oncology, a key business area, saw a significant increase, with revenue rising by 19% to $5.57 billion.
- Tagrisso, a cancer treatment, experienced a 14% increase in sales, reaching $1.67 billion.
- Calquence and Enhertu also showed strong growth, with sales rising by 24% and 50%, respectively.
3. **Expense Management**:
- The expenses ratio was not provided, but the company's financial guidance for the fiscal year 2024 was upgraded, forecasting a high-teens percentage increase in total revenue.
- This suggests that AstraZeneca managed expenses effectively to support the growth in revenue.

In conclusion, AstraZeneca's revenue in Q4 2024 was robust, with key business segments, particularly oncology, contributing significantly to the overall growth. The company's effective expense management further bolstered its financial performance.